Prediction: Eli Lilly Stock Could Reach $1,200 by End of 2026
Eli Lilly reported record revenue of $19.80B with 55.5% growth, but the stock has risen only 2.57% YTD to $1,098.57. The disconnect suggests potential upside to $1,200.
Key Numbers
Eli Lilly (NYSE:LLY) reported stellar Q4 2025 results, with revenue surging 55.5% year-over-year to $19.80 billion. Despite this, the stock has gained only 2.57% year-to-date, trading at $1,098.57. This gap between strong fundamentals and muted price action has led some analysts to predict a rally toward $1,200.
Key Financial Results
| Metric | Value |
|---|---|
| Revenue | $19.80B (55.5% YoY growth) |
| Mounjaro Revenue | $8.66B |
| Current Price | $1,098.57 |
| YTD Return | +2.57% |
Highlights from the Report
- Strong Mounjaro sales driven by diabetes and weight loss demand.
- Full-year revenue guidance raised to $82-85 billion.
- Robust operating margins supporting R&D investment.
Forward Guidance
Management raised 2026 revenue guidance to a range of $82-85 billion, signaling confidence in continued growth from Mounjaro and pipeline drugs.
Impact on the Stock
The stock's underperformance relative to earnings suggests the market has not fully priced in the company's growth trajectory. Some analysts view this as a buying opportunity.
What This Means for Investors
If Eli Lilly maintains its growth momentum, the stock could potentially reach $1,200. However, investors should monitor regulatory risks and competitive dynamics in the GLP-1 market.
Frequently Asked Questions
Found this useful? Share it